Category: Firm News

Malpractice “Reforms” Unrelated To The Practice Of Defensive Medicine

In direct contradiction to claims that medical malpractice caps are necessary on pain and suffering in order to reduce the costs of doctors practicing “defensive medicine, ” a recent study released in the policy journal Health Affairs found that many of the popular proposals suggested for reducing medical malpractice are unrelated to the practice of… read more


Traumatic Brain Injuries Often The Beginning Of A Disease Process

According to a recent study, traumatic brain injuries (TBIs) have now been linked to the onset of several debilitating diseases. Commonly associated with birth trauma, car accidents, and sport’s injuries, TBIs have now been shown to set off a neurological process associated with Alzheimer’s, sleep apnea, ALS or Lou Gehrig’s disease, and Parkinson’s disease. Complicating… read more


Senator Questions Company’s Response To Paid Consultant’s Complaints About Zimmer Durom Cup

In a letter, previously posted on the WSJ website, to Zimmer CEO David Dvorak, Senator Charles Grassley raised questions regarding how the company responds to criticisms concerning joint replacement products, including the Zimmer Durom Cup (also known as the Zimmer Durom Acetabular Cup), by physicians who are paid company consultants. Grassley has a history of… read more


New Reports Cite Safety Concerns Regarding Use Of Shoulder Pain Pumps

A previously issued report on the Anesthesiology News website indicated that shoulder pain pumps – pumps used to deliver intra-articular pain medication during surgery – may be causing more harm than good. Anesthesiology News joins the New York Times, the FDA, and hundreds of patients nationwide citing the potential for devastating and long-term shoulder injuries… read more






FDA AVANDIA Hearing – Day Two

07/14/10

Wednesday, July 14th, 2010 Today officials meet again in Gaithersburg, Maryland to discuss the fate of the diabetes drug Avandia. FDA decision-makers are given instructions to answer multiple-choice questions that start with the following: Please select the following: A. Avandia (Rosiglitazone) should continue on the market and the black box warning should be removed. B…. read more


FDA AVANDIA Hearing – Day Two update

07/14/10

The officials voting today were presented with multiple choice questions. Question three had a choice of A. The data provides sufficient evidence to raise significant safety concerns in diabetes type 2 patients taking Rosiglitazone (Avandia). B. The data does not provide sufficient evidence to raise significant safety concerns in diabetes type 2 patients taking Avandia…. read more